Cargando…

HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm

BACKGROUND: Recently, a Risk of Ovarian Malignancy Algorithm (ROMA) utilising human epididymis secretory protein 4 (HE4) and CA125 successfully classified patients as presenting a high or low risk for epithelial ovarian cancer (EOC). We validated this algorithm in an independent prospective study. M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Van Gorp, T, Cadron, I, Despierre, E, Daemen, A, Leunen, K, Amant, F, Timmerman, D, De Moor, B, Vergote, I
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3048204/ https://www.ncbi.nlm.nih.gov/pubmed/21304524 http://dx.doi.org/10.1038/sj.bjc.6606092

Ejemplares similares

Reply: The performance of the risk of ovarian malignancy algorithm
por: Van Gorp, T, et al.
Publicado: (2011)

Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts
por: Huhtinen, K, et al.
Publicado: (2009)

Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer
por: Hofstetter, G, et al.
Publicado: (2011)

Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells
por: Comamala, M, et al.
Publicado: (2011)

Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women
por: Cho, Hye Yon, et al.
Publicado: (2015)

A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses
por: Anton, Cristina, et al.
Publicado: (2012)

Symptoms, CA125 and HE4 for the preoperative prediction of ovarian malignancy in Brazilian women with ovarian masses
por: Pitta, Denise da Rocha, et al.
Publicado: (2013)

HE4, CA-125, and cystic ovarian mass
por: Wiwanitkit, Viroj
Publicado: (2012)

The power of the Risk of Ovarian Malignancy Algorithm considering menopausal status: a comparison with CA 125 and HE4
por: Han, Kyung Hee, et al.
Publicado: (2019)

Diagnostic usefulness of the Risk of Ovarian Malignancy Algorithm using the electrochemiluminescence immunoassay for HE4 and the chemiluminescence microparticle immunoassay for CA125
por: Chudecka-Głaz, Anita, et al.
Publicado: (2016)

Expression profiling to predict the clinical behaviour of ovarian cancer fails independent evaluation
por: Gevaert, Olivier, et al.
Publicado: (2008)

Proteomic biomarkers predicting lymph node involvement in serum of cervical cancer patients. Limitations of SELDI-TOF MS
por: Van Gorp, Toon, et al.
Publicado: (2012)

Identification of genes and pathways associated with cytotoxic T lymphocyte infiltration of serous ovarian cancer
por: Leffers, N, et al.
Publicado: (2010)

Increased chromosomal stability in cultures of ovarian tumours of low malignant potential compared to cystadenomas
por: Yu, J, et al.
Publicado: (2007)

Evaluation of serum CEA, CYFRA21-1 and CA125 for the early detection of colorectal cancer using longitudinal preclinical samples
por: Thomas, D S, et al.
Publicado: (2015)

Preoperative HE4 and ROMA values do not improve the CA125 diagnostic value for borderline tumors of the ovary (BOT) – a study of the TOC Consortium
por: Braicu, Elena Ioana, et al.
Publicado: (2014)

The chemokine, CXCL12, is an independent predictor of poor survival in ovarian cancer
por: Popple, A, et al.
Publicado: (2012)

Targeting EGFR and PI3K pathways in ovarian cancer
por: Glaysher, S, et al.
Publicado: (2013)

Elevated serum CXCL16 is an independent predictor of poor survival in ovarian cancer and may reflect pro-metastatic ADAM protease activity
por: Gooden, M J M, et al.
Publicado: (2014)

Ascitic complement system in ovarian cancer
por: Bjørge, L, et al.
Publicado: (2005)

Role of lymphangiogenesis in epithelial ovarian cancer
por: Sundar, S S, et al.
Publicado: (2006)

Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes
por: Shapira, I, et al.
Publicado: (2014)

Gene expression profiling of primary cultures of ovarian epithelial cells identifies novel molecular classifiers of ovarian cancer
por: Le Page, C, et al.
Publicado: (2006)

The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer
por: WEI, SU, et al.
Publicado: (2016)

Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review
por: Dochez, Vincent, et al.
Publicado: (2019)

Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer
por: Uno, K, et al.
Publicado: (2007)

An immunohistochemical perspective of PPARβ and one of its putative targets PDK1 in normal ovaries, benign and malignant ovarian tumours
por: Ahmed, N, et al.
Publicado: (2008)

Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer
por: Lambrechts, Sandrina, et al.
Publicado: (2015)

Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients
por: Bignotti, E, et al.
Publicado: (2011)

Pre-treatment ADC histogram-analysis at whole body diffusion-weighted MRI predicts disease free survival in ovarian cancer
por: Michielsen, K, et al.
Publicado: (2015)

Heparan sulphate synthetic and editing enzymes in ovarian cancer
por: Backen, A C, et al.
Publicado: (2007)

Androgen-related expression of G-proteins in ovarian cancer
por: Sheach, L A, et al.
Publicado: (2009)

Creation of immortalised epithelial cells from ovarian endometrioma
por: Bono, Y, et al.
Publicado: (2012)

Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy
por: Bellone, S, et al.
Publicado: (2013)

Urine CA125 and HE4 for the Detection of Ovarian Cancer in Symptomatic Women
por: Barr, Chloe E., et al.
Publicado: (2023)

Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel
por: Oikonomopoulou, K, et al.
Publicado: (2008)

Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal Women
por: Gentry-Maharaj, Aleksandra, et al.
Publicado: (2020)

miR-23a promotes IKKα expression but suppresses ST7L expression to contribute to the malignancy of epithelial ovarian cancer cells
por: Yang, Zhen, et al.
Publicado: (2016)

IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer
por: Abiko, K, et al.
Publicado: (2015)

c-FOS suppresses ovarian cancer progression by changing adhesion
por: Oliveira-Ferrer, L, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_i0si9l67acu0sda2gbqrvol31q